Cancer
Scientists use cold virus to treat bladder cancer
July 5, 2019Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus
A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …
Cancer cost US more than $94 billion in lost earnings in 2015
July 4, 2019Research and Development Cancer, economics, health, lost earnings, oncology, pharma
Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer …
Hospitals in Oxfordshire to test for susceptibility to dangers of chemotherapy
July 1, 2019Manufacturing and Production Cancer, Diagnostics, NHS, UK, breast, colon, oesophogus, pharma
Hospitals in Oxfordshire have introduced a genetic test which helps doctors predict the dangerous side effects of chemotherapy. In …
FDA greenlights Pfizer biosimilar version of Genentech’s Avastin
July 1, 2019Sales and Marketing Cancer, Genentech, Pfizer, pharma, pncology
Pfizer is celebrating the approval by the FDA of Zirabev, its biosimilar version of Genentech’s Avastin (bevacizumab), which is now …
Major review points to success of HPV vaccine, cervical cancer could be eradicated in developed nations
June 27, 2019Research and Development Cancer, HPV, UK, cervical cancer, human papilloma virus, pharma, vaccines
A major new review published in The Lancet has supported the effectiveness of the human papilloma virus (HPV) vaccine in …
NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population
June 19, 2019Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma
Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …
MSD’s Keytruda snatches up first approval in small cell lung cancer
June 19, 2019Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma
MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …
EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer
June 18, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …
Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours
June 18, 2019Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma
Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …
J&J and Colgate pay $4.8 million each to woman in California
June 13, 2019Business Services, Medical Communications Cancer, J&J, JJ, lawsuit, pharma, talc
A California court has said Johnson & Johnson and Colgate-Palmolive must pay a total of nearly $10 million to a …
Darzalex combo makes strong Phase 3 showing in multiple myeloma
June 4, 2019Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma
Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …
Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours
June 4, 2019Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS
Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …
Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer
June 3, 2019Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer
Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …
Isatuximab improves on standard of care treatments for multiple myeloma
June 3, 2019Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma
Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
Latest content
Five Facts about cardiovascular disease
